XORTX Therapeutics
XRTX
6 hedge funds and large institutions have $60.2K invested in XORTX Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 2 → 6 (+4)
1.69% more ownership
Funds ownership: 0.01% → 1.71% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$19.6K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$3.55K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$628 |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$472 |
Top Sellers
XRTX Hedge Fund Activity: Q2 2025 in Review
6 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q2 2025, worth a combined $60.2K — up 14,369% from $416 a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XRTX positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.3K.
- 6 institutional investors held XORTX Therapeutics (XRTX) as of Q2 2025, up from 2 in Q1 2025.
- Funds reported $60.2K of XORTX Therapeutics stock for Q2 2025, up 14,369% quarter-over-quarter.
- 4 funds opened new XORTX Therapeutics positions in Q2 2025 and 0 closed out, a net change of +4 holders.
- The largest XORTX Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $36.3K added.
Based on aggregated 13F filings for Q2 2025.